Fresh Equities
ASX:CDY

ASX:CDY

CELLMID LIMITED

CELLMID LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works
Authentication

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

Authentication

2. View Terms

View the full term sheet for the capital raise.

Authentication

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

9 October 2019

Capital Raise
Raised
$1.5m
Price at Close
$0.225
Market Cap
$18.81m
Re-listed
13-10-2019

Company Overview

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health.

Type

Listed Company

GICS Sub-industry

Biotechnology

Head Office

Suite 204, Level 2/55 Clarence St, Sydney NSW 2000, Australia

Biotechnology
Health Care
Biotech
Biotech & Health

Price Chart


Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Fresh Equities does not have CELLMID LIMITED quarterly cash flows data.


Directors


Announcements

All
All Time
  • Cellmid's Evolis Patent to be Granted in China on 3 February 2020

    Progress Report

  • Appendix 4C and Notes to Appendix 4C on 29 January 2020

    Commitments test entity quarterly reports

  • Key Midkine Antibody Patents Granted in the US and Europe on 5 January 2020

    Progress Report

  • Cellmid Reports on QVC Sales on 5 December 2019

    Progress Report

  • Change in substantial holding on 21 November 2019

    Shareholder Details

    Change of Director's Interest Notice - Eck on 21 November 2019

    Shareholder Details

    Change of Director's Interest Notice - Halasz on 21 November 2019

    Shareholder Details

    Appendix 3B and Cleansing Notice on 20 November 2019

    Issued Capital

    Results of Annual General Meeting on 19 November 2019

    Notice Of Meeting

    AGM Presentation to Shareholders on 19 November 2019

    Periodic Reports

    Load More

News

Fresh Equities does not have CELLMID LIMITED news data.